Trilexium 产品活性：Trilexium (TRX-E-009-1) 是第三代苯并吡喃，结构与 TRX-E-002-1 (HY-114250) 相关。Trilexium 增加 p21 蛋白表达并诱导细胞凋亡 (apoptosis)。Trilexium 解聚微管。Trilexium 显示出广泛的抗癌活性。 产品来源： https://www.medchemexpress.cn/trilexium.html 研究领域：Cytoskeleton | Apoptosis | Epigenetics | Cell Cycle/DNA Damage 作用靶点：Microtubule/Tubulin | Apoptosis | PARP | Caspase In Vitro: Trilexium shows activity against a broad range of cancer types. Of the 240 cell lines assessed in the Eurofin’s Oncopanel, 10 cell lines shows IC50 > 30 μM, of the remaining 230 cell lines, the average IC50 is 0.428 μM. Trilexium (300 nM, 4 h) disrupts microtubule networks in Hela cells. Trilexium (1-5 μM) leads to increased protein expression of p21, c-PARP, and c-Caspase 3 in HSJD-DIPG007 cells. Trilexium (0-2 μM) restores H3K27 trimethylation and increases H3K27 acetylation in HSJD-DIPG007 cells. In Vivo: Trilexium (5-60 mg/kg, IV daily for 15 days) significantly reduces tumour volume in vivo. Trilexium (80 mg/kg, IV daily for 5 days) disrupts microtubules in vivo. 相关产品：Bioactive Compound Library Plus | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Olaparib | Y-27632 | LY294002 | Paclitaxel | Z-VAD-FMK | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | Actinomycin D | SB-431542 | 5-Fluorouracil | Bortezomib | Deferoxamine mesylate | Oxaliplatin | Trametinib | Sorafenib | Temozolomide | Gemcitabine | Decitabine | Mdivi-1 | Rotenone | Etoposide | Elesclomol | Ruxolitinib | Monomethyl auristatin E 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。